Mark J. Foley - 15 Mar 2022 Form 4 Insider Report for Revance Therapeutics, Inc.

Role: Chief Executive Officer, Director
Signature: /s/ Terri McDowell, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 15 Mar 2022
Net transactions value: -$52,170
Form type: 4
Filing time: 17 Mar 2022, 17:54:02 UTC
Previous filing: 04 Feb 2022
Next filing: 06 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVNC	Common Stock	Tax liability	$52,170	-3,304	-0.43%	$15.79	765,761	15 Mar 2022	Direct	F1
holding	RVNC	Common Stock						110,913	15 Mar 2022	See footnote	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 40,715 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
F2	These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.

Content

Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 40,715 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.

These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.